Full View

Migraine evolution after the cessation of CGRP (-receptor) antibody prophylaxis: a prospective, longitudinal cohort study

B Raffaelli, M Terhart, LH Overeem… - …, 2022 - journals.sagepub.com
Background National and international guidelines recommend stopping migraine
prophylaxis with CGRP (-receptor) monoclonal antibodies after 6–12 months of successful …
被引用次数：61 相关文章

Migraine evolution after the cessation of CGRP (-receptor) antibody prophylaxis: a prospective, longitudinal cohort study.

B Raffaelli, M Terhart, LH Overeem… - …, 2022 - search.ebscohost.com
Background: National and international guidelines recommend stopping migraine
prophylaxis with CGRP (-receptor) monoclonal antibodies after 6–12 months of successful …

Migraine evolution after the cessation of CGRP (-receptor) antibody prophylaxis: a prospective, longitudinal cohort study.

B Raffaelli, M Terhart, LH Overeem… - … Journal of Headache, 2021 - europepmc.org
Background National and international guidelines recommend stopping migraine
prophylaxis with CGRP (-receptor) monoclonal antibodies after 6-12 months of successful …

Migraine evolution after the cessation of CGRP (-receptor) antibody prophylaxis: a prospective, longitudinal cohort study

B Raffaelli, M Terhart, LH Overeem… - Cephalalgia: an …, 2022 - pubmed.ncbi.nlm.nih.gov
Background National and international guidelines recommend stopping migraine
prophylaxis with CGRP (-receptor) monoclonal antibodies after 6-12 months of successful …
[HTML] nih.gov

[HTML][HTML] Migraine evolution after the cessation of CGRP (-receptor) antibody prophylaxis: a prospective, longitudinal cohort study

B Raffaelli, M Terhart, LH Overeem, J Mecklenburg… - …, 2022 - ncbi.nlm.nih.gov
Background National and international guidelines recommend stopping migraine
prophylaxis with CGRP (-receptor) monoclonal antibodies after 6–12 months of successful …